Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) AI Stock Analysis

Jagsonpal Pharmaceuticals Ltd.

(NSE:JAGSNPHARM)

Select Model

Rating:76Outperform

Price Target:INR 270.00▲(24.48% Upside)

Action:reiterated

Date:08/06/26

Strong financial performance with stable balance sheet and growth potential drives the score, supported by positive technical momentum; moderate valuation tempers enthusiasm due to high P/E.

Positive Factors

Very Low LeverageMinimal debt reduces financial risk and interest burden, giving Jagsonpal flexibility to fund product development, sales expansion, and working-capital needs without materially increasing balance-sheet pressure.

Negative Factors

Earnings VolatilityFalling earnings despite stronger reported revenue suggests inconsistent conversion of growth into profit, making future profitability less predictable and potentially limiting confidence in the durability of recent expansion.

Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 11.37B
Dividend Yield: 1.84%
Average Volume (3M): 13.36K
Price to Earnings (P/E): 31.9
Beta (1Y): 1.04
Revenue Growth: 11.71%
EPS Growth: -26.92%
Country: India
Employees: 1,297
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Jagsonpal Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Jagsonpal Pharmaceuticals Limited, an Indian company founded in 1964 and based in New Delhi, specializes in the development and manufacturing of both bulk active pharmaceutical ingredients and diverse medicinal formulations. Its product portfolio spa...

How the Company Makes Money

Jagsonpal Pharmaceuticals primarily makes money by selling pharmaceutical formulations (finished dosage medicines) in the Indian market. Revenue is generated through (1) domestic sales of branded formulations to channel partners such as stockists/dis...

Jagsonpal Pharmaceuticals Ltd. Financial Statement Overview

Summary

Solid overall with income statement at 75 reflecting revenue growth and improving margins despite volatility, balance sheet at 85 showing strong stability and low debt, and cash flow at 70 indicating positive but inconsistent trends.

Income Statement

75Positive

Balance Sheet

85Very Positive

Cash Flow

70Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	2.94B	2.87B	2.69B	2.09B	2.37B	2.18B
Gross Profit	1.63B	1.83B	1.72B	652.59M	1.44B	1.28B
EBITDA	681.92M	679.90M	510.71M	323.46M	362.61M	284.29M
Net Income	454.76M	430.82M	553.61M	224.63M	267.21M	188.55M
Balance Sheet
Total Assets	0	3.17B	2.78B	2.17B	1.95B	1.68B
Cash, Cash Equivalents and Short-Term Investments	1.06B	1.06B	1.29B	1.48B	1.15B	472.77M
Total Debt	0	81.65M	92.39M	89.41M	60.01M	52.47M
Total Liabilities	-2.76B	405.05M	383.10M	296.76M	360.56M	375.99M
Stockholders Equity	2.76B	2.76B	2.40B	1.87B	1.59B	1.31B
Cash Flow
Free Cash Flow	245.77M	466.64M	549.52M	349.18M	463.37M	51.31M
Operating Cash Flow	246.75M	468.12M	553.00M	351.66M	466.54M	55.98M
Investing Cash Flow	-82.07M	-356.49M	-451.47M	-245.48M	-576.71M	-257.79M
Financing Cash Flow	-148.90M	-121.49M	-116.98M	-89.11M	-4.57M	-175.52M

Jagsonpal Pharmaceuticals Ltd. Technical Analysis

Technical Analysis SentimentNegative

Last Price216.90

Price Trends

50DMA229.80Negative

100DMA226.14Negative

200DMA205.33Positive

Market Momentum

MACD-2.93Negative

RSI42.56Neutral

STOCH57.29Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JAGSNPHARM, the sentiment is Negative. The current price of 216.90 is below the 20-day moving average (MA) of 223.43, below the 50-day MA of 229.80, and above the 200-day MA of 205.33, indicating a neutral trend. The MACD of -2.93 indicates Negative momentum. The RSI at 42.56 is Neutral, neither overbought nor oversold. The STOCH value of 57.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JAGSNPHARM.

Jagsonpal Pharmaceuticals Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:JAGSNPHARM against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:SYNCOMF	80Outperform	INR 18.09B	21.14	―	0.52%	0.44%	48.60%
IN:JAGSNPHARM	76Outperform	INR 14.33B	31.87	―	1.84%	11.71%	-26.92%
IN:VENUSREM	69Neutral	INR 16.46B	13.61	―	0.82%	20.22%	73.03%
IN:LINCOLN	67Neutral	INR 10.05B	10.37	―	0.36%	10.20%	11.70%
IN:SAKAR	66Neutral	INR 20.74B	49.03	―	―	47.99%	117.99%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:INDSWFTLAB	51Neutral	INR 31.95B	53.99	―	―	66.39%	-72.31%

* General Sector Average

Performance Comparison

IN:JAGSNPHARM and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:JAGSNPHARM	Jagsonpal Pharmaceuticals Ltd.	216.90	-5.32	-2.40%
IN:INDSWFTLAB	Ind-Swift Laboratories Ltd.	367.40	265.25	259.67%
IN:LINCOLN	Lincoln Pharmaceuticals Ltd	501.95	-29.59	-5.57%
IN:SAKAR	Sakar Healthcare Ltd	944.80	572.70	153.91%
IN:SYNCOMF	Syncom Formulation (India) Ltd.	19.25	2.69	16.26%
IN:VENUSREM	Venus Remedies Limited	1231.75	791.09	179.52%

Jagsonpal Pharmaceuticals Ltd. Corporate Events

Jagsonpal Pharma Publishes Q1 FY27 Earnings Call Transcript

Aug 4, 2026

Jagsonpal Pharmaceuticals Limited announced that it has released the official transcript of its Q1 FY27 earnings conference call, which was held on July 30, 2026, to discuss the company’s financial results for the quarter. The transcript, prepa...

Jagsonpal Pharmaceuticals Publishes Q1 FY27 Earnings Call Transcript

Aug 4, 2026

Jagsonpal Pharmaceuticals Limited has released the transcript of its Q1 FY27 earnings conference call, which was held on July 30, 2026, to discuss its financial results for the quarter. The document, filed with both the BSE and NSE under regulatory d...

Jagsonpal Pharma Grants 120,000 ESOPs Under 2022 Plan

Jul 29, 2026

Jagsonpal Pharmaceuticals Ltd. has approved the grant of 120,000 employee stock options under its 2022 ESOP plan at an exercise price of Rs 179.25 per option. The options are convertible into an equal number of equity shares with a face value of Rs 2...

Jagsonpal Pharma Secures Controlling Stake in Aequitas Healthcare

Jul 7, 2026

Jagsonpal Pharmaceuticals Limited has advanced its expansion strategy in the Indian healthcare market by acquiring a controlling equity stake in Aequitas Healthcare Private Limited. The listed pharmaceutical company, traded on BSE and NSE as JAGSNPHA...

Jagsonpal Pharma Promoters Report No Share Encumbrances for FY 2026

Jun 30, 2026

Jagsonpal Pharmaceuticals Ltd., a listed Indian drug maker traded on BSE and NSE, has disclosed annual promoter shareholding details under the Securities and Exchange Board of India’s takeover regulations for the year ended March 31, 2026. The...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 06, 2026

Jagsonpal Pharmaceuticals Ltd. AI Stock Analysis